August 09, 2026 10:14 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘A morning I will cherish’: Raghav Chadha meets PM Modi, shares photos from ‘enriching’ meeting | Delhi Mercedes crash kills 70-year-old woman: Cop’s son behind wheel, beer bottle found | Indian-origin woman accused of ‘visa fraud’ on X: US Attorney steps in with major clarification | US Senate passes Russia sanctions bill: India can face Trump’s 100% tariff threat | Expired meat, rotten vegetables found at Bengaluru's luxury hotels, legal action begins | 'I'm ready to be humiliated': Vijay, Udhayanidhi Stalin clash in Tamil Nadu Assembly over Cauvery dispute | 'They don't need Mohan Bhagwat's certificate': Priyanka Gandhi Vadra's sharp reply to RSS chief's Gen Z remark | 'Students, Gen Z, ask me anything': Rahul Gandhi launches Instagram Q&A, responds to Jharkhand protest | PM Modi goes Gen Z, urges Indians to share 'Get Ready With Me' videos on National Handloom Day | Former Tehelka editor Tarun Tejpal sentenced to 10-year jail term in 2013 rape case as Bombay HC overturns acquittal
ZyCoVD
Image Credit: Pixabay

Zydus Cadila seeks DCGI's emergency use approval for its 3-dose, 'needle free' vaccine : Reports

| @indiablooms | Jul 01, 2021, at 09:13 pm

New Delhi/IBNS: Gujarat-based pharma company Zydus Cadila has sought Drugs Controller General of India's (DCGI) approval for emergency use of its ZyCoV-D three-dose Covid shot which is the "world's first Plasmid DNA vaccine" and safe for children above the age of 12, according to media reports.

According to Reuters, the company has provided the interim results from phase III clinical trials that involved over 28,000 volunteers, across the country, including about 1,000 subjects in the 12-18 year age group, Zydus says.

The study was carried out "during the peak of the second wave of COVID-19 (in India), reaffirming the vaccine's efficacy against the new mutant strains, especially the Delta variant," Zydus said in a statement to the stock exchanges, according to Reuters.

The company claims 66.6 per cent efficacy of the vaccine against symptomatic Covid cases and 100 per cent for moderate infections.

The vaccine was found to be safe for children between 12 and 18 years but its trial data is awaiting peer-review.

The vaccine is ideally stored at 2 to 8 degree Celsius but has shown good stability at temperatures of 25degrees for at least three months, says the company, easing difficulties faced in transporting and storing coronavirus vaccines and also reduces any cold chain breakdown challenges.

"Also, being a plasmid DNA vaccine, ZyCoV-D doesn't have any problem associated with vector based immunity," the company says in a statement.

A plasmid DNA vaccine works by producing the spike protein of the coronavirus and subsequently inciting an immune response, Zydus says, adding thatifications can be made to the plasmid DNA platforms to deal with new mutations.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.